Global Primary Immunodeficiency Diseases Treatment Market 2017-2021

This industry research report identifies CSL Behring, Grifols, Pfizer, and Shire as the key vendors in the global primary immunodeficiency diseases treatment market. This industry research report also presents a comprehensive analysis of the market by therapy (immunoglobulin therapy, antibiotics, and others) and by geography (the Americas, APAC, and EMEA).

Overview of the global primary immunodeficiency diseases treatment market

Technavio’s market study identifies that the growing number of fractioning units will be one of the primary factors for the primary immunodeficiency diseases treatment market growth. Fractionation separates the immunoglobulins and blood protein from plasma, which in turn, results in the development of immunoglobulins. Immunoglobulin therapy is useful in reducing the symptoms of autoimmune disease and a wide range of infections as they easily detect the microorganisms that are entering the body and assist the immune cells in neutralizing them. Technavio’s market analysts estimate that the market will grow steadily at a CAGR of more than 6% by 2021.

The development of immunoglobulin therapy for primary immunodeficiency diseases (PIDDs) is growing steadily and is impacting the primary immunodeficiency diseases treatment market worth. Plasma donors are paid to maintain and meet the demands of plasma-derived therapeutics. The provision of financial aid for plasma donors is identified as one of the key trends contributing towards the growth of the primary immunodeficiency diseases treatment market. Providing financial aid to the plasma donors will increase the number of donors available in the future, catering to the demand for plasma-derived therapeutics.

Competitive landscape and key vendors

The primary immunodeficiency diseases treatment market is populated due to the presence of several established international and domestic players. Manufacturers in this market compete intensely in terms of factors such as advances in technology, increased inorganic growth strategies, and increase in the capacity of fractionating units. To remain competitive in the primary immunodeficiency symptoms treatment market, vendors are implementing strategies such as M&A, distribution partnerships, and pricing strategies. Advanced technologies are integrated in products to develop the product portfolio.

The leading vendors in the market are

• CSL Behring
• Grifols
• Pfizer
• Shire

The other prominent vendors in the market are Abbott, ADMA Biologics, Astellas, AstraZeneca, Baxter, Bayer, Biocon, Bristol-Myers Squibb, BDI Pharma, Bharat Serums and Vaccines, Eli Lilly, GlaxoSmithKline, Hualan Biological Engineering, Kedrion Biopharma, LFB Group, Lupin Pharmaceuticals, Mylan, Novartis, Octapharma, Sanofi, Sanquin, Takeda Pharmaceutical Company, Valneva, and Wockhardt.

Segmentation by therapy and analysis of the primary immunodeficiency diseases treatment market

• Immunoglobulin therapy
• Antibiotics

Primary immunodeficiency diseases (PIDDs) impact the body’s immunity by producing limited or negligible immunoglobulins. Immunoglobulin therapy protects against several infections and reduces the autoimmune disease symptoms. This therapy is used to treat various PIDDs and is required throughout the lifetime. 

Geographical segmentation and analysis of the primary immunodeficiency diseases treatment market

• Americas
• APAC
• EMEA

The Americas, primarily the US, is witnessing a high investment in R&D and the healthcare segment. Factors such as improved treatment regimen, awareness about rare and fatal diseases, technological advancement, and increase in disease prevalence rate drives the market growth in the region. Also, the increasing focus on rare diseases is demanding for PIDD treatment drugs that is contributing towards the growth of the primary immunodeficiency diseases treatment market in the Americas.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global primary immunodeficiency diseases treatment market?
• What are the key market trends impacting the growth of the global primary immunodeficiency diseases treatment market?
• What are the challenges to market growth?
• Who are the key vendors in the global primary immunodeficiency diseases treatment market?
• What are the market opportunities and threats faced by the vendors in the global primary immunodeficiency diseases treatment market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global primary immunodeficiency diseases treatment market?

Technavio also offers customization on reports based on specific client requirement.